New Delhi: Cipla Limited has signed definitive agreements for investment in optionally convertible preference shares of iCaltech Innovations Private Limited, subject to completion of certain conditions.
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus, with a core focus on respiratory care.
Commenting on the development, Achin Gupta, Global COO, Cipla Limited said, “As lung leaders, our decision to invest in iCaltech reflects Cipla’s commitment to advancing respiratory diagnostics. With the aim to reduce the existing gap in the current ecosystem, our strategic funding will enable iCaltech to further expand and develop innovative devices. We remain committed towards providing easy access to high-quality diagnostic solutions across India.”
Strategic partnerships remain central to Cipla’s innovation engine, as the company continues to expand its digital, devices and diagnostics offerings and build on its legacy of lung leadership.
Dr Sagar Sengupta, Director, National Institute of Biomedical Genomics (NIBMG) and Director (Additional Charge), National Brain Research Centre (NBRC) shared his insights on the latest initiatives, importance of industry-academia collaboration, increased government funding, and evolution of research ecosystem
Binoy Gardi, Managing Director and Group CEO, Veeda Lifesciences shared insights on his latest role and top priorities; the company's latest initiatives, outcomes of key acquisitions and future plans